Trial · NCT01020968
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of major adverse cardiac event (MACE) (MACE defined as: cardiac death, cardiac arrest, myocardial infarction, sustained ventricular arrhythmias, pulmonary edema, acute heart failure, unstable angina and major bleeding) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Left ventricular ejection fraction (LVEF) (As determined by Echo, Cardiac CT and SPECT) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12. CT and SPECT are only assessed at Baseline and Month 6. | |
| Secondary | Change in LV and RV dimensions and in LV volumes (As determined by Echo, Cardiac CT and SPECT) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12. CT and SPECT are only assessed at Baseline and Month 6. | |
| Secondary | Wall Motion Score Index (WMSI) (As determined by Echo, Cardiac CT and SPECT) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12. CT and SPECT are only assessed at Baseline and Month 6. | |
| Secondary | Assessment of myocardial perfusion in ischemic patient cohort, only (As determined by SPECT) | Baseline and Month 3 | |
| Secondary | Exercise tolerance (6 minute walk test) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Heart failure status (As determined by New York Heart Association (NYHA) heart failure status (NYHA) class and Brain Natriuretic Peptide [BNP]) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Angina status (As determined by Canadian Cardiovascular Society (CCS) classification and Troponin I Levels) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Quality of life (As determined by Minnesota Living with Heart Failure Questionnaire [MLHFQ]) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Pulmonary function (As determined by metabolic stress test) | Baseline, Month 6 and Month 12 | |
| Secondary | Device implantation, transplantation and positive inotrope use (As determined by incidence rates) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | AICD firing rate | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Changes in medication for heart failure | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01020968/registered